Navigation Links
AstraZeneca submits an sNDA for Symbicort for treatment of asthma in children as young as 6
Date:6/4/2008

Wilmington, DE June 4, 2008 AstraZeneca (NYSE: AZN) today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the long-term maintenance treatment of asthma in pediatric patients ages 6 to 11 years old. SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.

"Millions of children in the U.S. are affected by asthma1," said lead investigator Jeffrey Leflein, MD, Allergy & Immunology Associates of Ann Arbor, Michigan. "SYMBICORT could potentially offer another treatment option for the long-term maintenance of asthma in young children whose condition is not adequately controlled with inhaled corticosteroids alone."

The submission package is based on a robust clinical development program consisting of five active or placebo-controlled Phase III trials assessing the efficacy and safety of SYMBICORT pressurized metered-dose inhaler (pMDI) that included 1,446 children ages 6 to 11 years old with asthma.2 The proposed starting dose for children (80/9 mcg twice-daily) was studied in one pivotal randomized, double-blind, active-controlled, 12-week study that evaluated 256 children ages 6 to 11 years old with mild-to-moderate persistent asthma previously treated with inhaled corticosteroid therapy.3 In this study, SYMBICORT was compared to budesonide pMDI and formoterol dry powder inhaler.3 A second study evaluating this dose included 351 subjects ages 6 to 11 years old.4 Results from both studies demonstrated that SYMBICORT 80/9 mcg twice daily had a similar safety profile to one of the mono-components, budesonide;4,5 likewise, results from the first study also found that SYMBICORT 80/9 mcg twice daily had a similar safety profile to its other mono-component, formoterol.5 The most common adverse events reported were headache, pyrexia, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain.2

"This sNDA submission is another important milestone for SYMBICORT, and we look forward to discussions with the FDA about the potential indication for children," said Howard Hutchinson, Chief Medical Officer, AstraZeneca. "AstraZeneca remains committed to advancing the treatment of asthma in adult and pediatric patients."


'/>"/>

Contact: Katie Neff
katie.neff@astrazeneca.com
302-885-9960
Edelman Public Relations
Source:Eurekalert

Related medicine news :

1. FDA Approves AstraZenecas Seroquel(R) for Maintenance Treatment in Bipolar Disorder
2. A Drug That Carries a Lower Risk of Weight Gain Than AstraZenecas Seroquel and Has Antimanic and Antidepressant Effects Would Earn a 30 Percent Patient Share in Bipolar Disorder Treatment
3. Washington University in St. Louis and AstraZeneca Announce Alzheimers Research Collaboration
4. Solcara Helps AstraZeneca Set International Benchmark for Global Media Relations
5. AstraZeneca Gives $1.5 million to Support North Carolina Worksite Wellness Project
6. AstraZeneca - Biologics Day Interviews With Senior Management
7. AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA
8. AstraZeneca Response to November 2, 2007 Ruling In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, U.S. District Court, District of Massachusetts
9. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
10. Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca
11. NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Sugar Land, TX (PRWEB) , ... February 12, ... ... the families of southwest Houston and surrounding communities by continuing it’s commitment to ... Fort Bend Family Promise. The organization works closely with area homeless families to ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic ... for Health Plans and PBMs,” an upcoming Feb. 24 webinar that will discuss ... in big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and ...
(Date:2/12/2016)... , ... February 12, 2016 , ... A lot has ... 35 years. A president has access to health and wellness resources most Americans could ... world, no single individual has a schedule as frenetic as the U.S. President. ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... the field of long term care. With that, says Patrick Loughney, president of ... in administrative roles in long term care environments. His company, which offers prep ...
(Date:2/12/2016)... ... ... Planet Future is a Final Cut Pro X themed package ... pictures, videos as well as text in an exciting cartoon environment. Planet Future is ... beautiful frame overlay. Pixel Film Studios makes editing easy; simply insert media into the ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016  Eli Lilly and Company (NYSE: LLY ) ... (pemetrexed disodium) vitamin regimen patent would not presently be infringed ... France , Italy and ... only with dextrose solution.  --> ... of Appeal held that Lilly,s patent would be indirectly infringed ...
(Date:2/12/2016)... Ungarn, February 12, 2016 ... sich auf den ungedeckten medizinischen Bedarf bei ... Ergebnisse seines klinischen Forschungsprogramms bekannt. Das Programm, ... ergab Verbesserungen ihrer respiratorischen Funktionen und anderer ... , ein Medizintechnikunternehmen, das sich auf den ...
(Date:2/11/2016)... -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for ... Company also filed its Quarterly Report on Form 10-Q for ... and Exchange Commission today. --> ... --> --> Net sales for the three ... to $5.4 million from $2.8 million for the three months ...
Breaking Medicine Technology: